Alembic Pharma gets USFDA nod for erectile dysfunction drug

Alembic Pharmaceuticals has said it has received approval from the US health regulator for Tadalafil tablets, indicated for the treatment of erectile dysfunction. The approval from the USFDA, is for the company’s abbreviated new drug application (ANDA) for Tadalafil tablets USP, in the strengths of 2.5 mg, 5mg, 10mg and 20 mg.

The approval from the United States Food and Drug Administration (USFDA) is for the company’s abbreviated new drug application (ANDA) for Tadalafil tablets USP, in the strengths of 2.5 mg, 5mg, 10mg and 20 mg, Alembic Pharmaceuticals said in a filing to BSE.

The product is generic version of Eli Lilly and Company’s Cialis tablet.

Quoting IQVIA data, Alembic Pharma said Tadalafil Tablets have an estimated market size of $1.8 billion for twelve months ending December 2018.

The company currently has a total of 89 ANDA approvals (77 final approvals and 12 tentative approvals) from USFDA, it added.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.